Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Notes Receivable: ¥0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600211 Tibet Rhodiola Pharmaceutical Holding Co SHSE:600211
94 GF Score
Price ¥39.30
GF Value ¥40.53
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Tibet Rhodiola Pharmaceutical Holding Co Notes Receivable?

Tibet Rhodiola Pharmaceutical Holding Co SHSE:600211 +1.39% 94 Notes Receivable is ¥0 Mil as of Mar. 2026. GuruFocus rates SHSE:600211 with a GF Score™ of 94/100 and a GF Value™ of ¥40.53 (Fairly Valued). The stock has 2 warning signs investors should review.

Tibet Rhodiola Pharmaceutical Holding Co's Notes Receivable for the quarter that ended in Mar. 2026 was ¥0 Mil.

Tibet Rhodiola Pharmaceutical Holding Co Notes Receivable Related Terms

Tibet Rhodiola Pharmaceutical Holding Co Notes Receivable Historical Data

* Premium members only.

The historical data trend for Tibet Rhodiola Pharmaceutical Holding Co's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tibet Rhodiola Pharmaceutical Holding Co Notes Receivable Chart

Tibet Rhodiola Pharmaceutical Holding Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Tibet Rhodiola Pharmaceutical Holding Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SHSE:600211
94GF Score
Tibet Rhodiola Pharmaceutical Holding Co SHSE:600211
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tibet Rhodiola Pharmaceutical Holding Co Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of ¥0 Mil mean?
Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) has a Notes Receivable of ¥0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Tibet Rhodiola Pharmaceutical Holding Co and its competitors.
Is Tibet Rhodiola Pharmaceutical Holding Co's Notes Receivable too high?
Tibet Rhodiola Pharmaceutical Holding Co's current Notes Receivable is ¥0 Mil. Overall, Tibet Rhodiola Pharmaceutical Holding Co has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tibet Rhodiola Pharmaceutical Holding Co's Notes Receivable compare to ZTS and UTHR?
Tibet Rhodiola Pharmaceutical Holding Co's Notes Receivable of ¥0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Tibet Rhodiola Pharmaceutical Holding Co and its competitors. Tibet Rhodiola Pharmaceutical Holding Co's current Notes Receivable is ¥0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tibet Rhodiola Pharmaceutical Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) is currently considered Fairly Valued. The stock's GF Value™ is ¥40.53, compared to a current price of ¥39.30 — trading 3% below its estimated fair value. The current Notes Receivable is ¥0 Mil. Tibet Rhodiola Pharmaceutical Holding Co's overall GF Score™ is 94/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211), the current Notes Receivable is ¥0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Overvalued in 2026?

Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co stock appears to be undervalued. The current stock price of ¥39.30 is trading 3% below its estimated GF Value™ of ¥40.53. GuruFocus considers Tibet Rhodiola Pharmaceutical Holding Co to be Fairly Valued.

Key valuation signals for SHSE:600211:

  • Notes Receivable: ¥0 Mil
  • GF Value™: ¥40.53 vs. price of ¥39.30 (3% below fair value)
  • GF Score™: 94/100 with 2 warning signs

No single metric tells the full story. See the SHSE:600211 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tibet Rhodiola Pharmaceutical Holding Co Business Description

Address No. 3 Guangzhou Road, Area A, Lhasa Economic and Technological Development Zone, Tibet Autonomous Region, Lhasa, CHN, 850000
Tibet Rhodiola Pharmaceutical Holding Co is a pharmaceutical company engaged in the production and sales of capsules, biological agents, granules, and coatings. The company's products cover biopharmaceuticals, Tibetan medicine, traditional Chinese medicine, and chemical drugs, involving fields such as cardiovascular and cerebrovascular diseases, hepatobiliary diseases, orthopedic pain relief, rheumatism, and cold medicines.
94GF Score

Get the complete analysis for SHSE:600211

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥39.30
Price
¥40.53
GF Value